Blume-Jensen Peter 4

What Happened
Peter Blume-Jensen, President, CEO and a Director of Acrivon Therapeutics, had 1,743 shares withheld by the company to satisfy mandatory tax withholding upon vesting of restricted stock units. The filing shows two withholding entries on May 14, 2026: 1,253 shares at $1.92 ($2,406) and 490 shares at $1.92 ($941), for a combined value of approximately $3,347. This is a tax-withholding disposal (transaction code F), not an open-market sale.

Key Details

• Transaction date: 2026-05-14. Filing date: 2026-05-18 (filed within two business days; timely).
• Entries: 1,253 shares @ $1.92 = $2,406; 490 shares @ $1.92 = $941; total 1,743 shares, ~$3,347.
• Transaction type: F — shares withheld by issuer to satisfy mandatory tax withholding on vested RSUs (not a market sale).
• Shares owned after transaction: not specified in the provided excerpt of the filing (see the full Form 4 for total holdings).
• Footnotes: F1 confirms issuer withheld shares for tax withholding. F2 and F3 note spouse holdings/disclaimers (Dr. Kristina Masson is spouse; each disclaims beneficial ownership of the other's separate holdings except to the extent of pecuniary interest).

Context
Withholding shares to pay taxes on vested RSUs is a routine administrative action and does not necessarily signal the insider selling shares for investment reasons. The dollar amount here (~$3.3k) is small. For retail investors, outright purchases or open-market sales are generally more informative about insider sentiment than tax withholdings.